DBAC DBAC DBAC DBAC
  • Dansk BørneAstma Center
    • Om DBAC
    • Beliggenhed
    • Fonde og donationer
    • Persondatapolitik
  • Børneastma
    • Generelt om astma hos børn
    • Asthma hos små børn
    • Astma hos større børn
    • Generel astma behandling
    • Astmabehandling småbørn
    • Astmabehandling større børn
    • Undersøgelser
    • Gode råd
    • Litteratur til forældre
  • Allergi og eksem
    • Generelt om allergi
    • Mælkeallergi
    • Generelt om eksem
  • Kliniske studier
    • COPSAC 2010 (ABC)
    • COPSAC-Severe
    • COPSAC Acute (Antibiotika)
  • Video

Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.

    Home Publications Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.
    NextPrevious

    Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.

    By Dansk Børne Astma Center | Publications | Comments are Closed | 11 december, 2001 | 0

    Chest. 2001 Dec
    Bisgaard H, Price MJ, Maden C, Olsen NA.

    Abstract
    STUDY OBJECTIVES:
    To evaluate the cost-effectiveness of inhaled fluticasone propionate (FP) in children aged 12 to 47 months with asthma symptoms.

    DESIGN:
    A retrospective economic analysis conducted from the perspective of the Danish health-care system, based on clinical data from a 12-week study.

    SETTING:
    Thirty-three outpatient centers in nine countries.

    PATIENTS:
    Two hundred thirty-seven children aged 12 to 47 months with documented history of recurrent wheeze or asthma symptoms.

    INTERVENTIONS:
    Two dosages of FP, 100 microg/d and 200 microg/d, and placebo administered in two divided doses via a metered-dose inhaler and a Babyhaler (Glaxo Wellcome; Middlesex, UK) spacer device.

    MEASUREMENTS:
    Effectiveness in terms of asthma exacerbations, control of cough and wheeze symptoms, symptom-free days, overall direct costs of asthma management in Danish kroner at 1999 prices, and mean and incremental cost-effectiveness ratios.

    RESULTS:
    FP, 200 microg/d, was significantly more effective than placebo treatment in terms of the proportion of exacerbation-free patients (73.7% vs 59.8%; p = 0.025) and patients experiencing a > or = 25% improvement in cough symptoms (57.9% vs 39.0%; p = 0.018). The costs per exacerbation-free patient, per patient with a > or = 25% improvement in cough and wheeze symptoms from baseline, and per symptom-free day were lower in the FP groups than in the placebo group. The incremental cost-effectiveness ratios for these end points indicated that the additional benefits of FP, 200 microg/d, were achieved at a lower overall cost compared with placebo treatment.

    CONCLUSIONS:
    From the perspective of the Danish health-care system, FP, 100 microg bid, administered via the Babyhaler inhalation device was cost-effective
    relative to standard therapy with bronchodilators alone.

    Comment in
    Pharmacoeconomics in pediatric asthma. [Chest. 2001]
    Fluticasone vs placebo in toddlers with asthma: good science or questionable ethics? [Chest. 2002]

    PMID: 11742910

    No tags.
    NextPrevious


    KONTAKT

    DBAC
    Dansk BørneAstma Center
    Herlev og Gentofte Hospital
    Telefon +45 3867 7360
    kontakt@dbac.dk
    DBAC • Herlev og Gentofte Hospital • Danmark © 2023
    • 20200227-P4-morgen-Rikke
    • Astma hos skolebørn
    • Astma hos små børn (Bisgaard)
    • COPSAC Acute (Antibiotika)
    • COPSAC informationsaften
    • COPSAC-Severe
    • Dansk BørneAstma Center
      • ABC-DK
      • Forebyggelse
      • Forskning
      • Forskningscentre
      • Generelt om allergi
      • Generelt om eksem
      • Input fra COPSAC familier
      • Knud har tabt pusten
      • Metoder
      • Nyheder
      • Om astma
        • Generel astma behandling
          • Astmabehandling småbørn
          • Behandling af astma hos større børn
        • Generelt om astma hos børn
          • Asthma hos små børn
          • Astma hos større børn
        • Gode råd
        • Undersøgelser
      • Om DBAC
        • Beliggenhed
        • Bestyrelsen
        • Fonde
        • Hjælp os med at hjælpe
        • Jobs
        • Kontakt
        • Litteratur til forældre
        • Patient- og lægeorganisationer
        • Persondatapolitik
        • Sponsorer
      • Spil
      • Undersøgelser
      • video
    • FAVORIT
    • Forebyggelse af astma hos børn (TEST-tilmelding)
    • Forebyggelse af astma hos børn (TEST)
    • Hans Bisgaard
    • Hans Bisgaard nekrolog
    • Indeklima og sundhed på Bellahøj
    • Lokale steroider for børn med astma
    • Mælkeallergi
    • myter og fakta om børneastma
    • Persondatapolitik
    DBAC